Abstract: Disclosed herein are oral care compositions comprising at least one phosphate/acrylate copolymer, at least one cationic antibacterial agent, at least one synthetic anionic linear polycarboxylate polymer, at least one surfactant, and zinc lactate. Also disclosed herein are methods for the treatment and/or inhibition of gum disease or halitosis comprising contacting the oral cavity with the oral care compositions disclosed herein, as well as methods of making the oral care compositions disclose herein.

Abstract: The present invention relates to improved complexes of amorphous calcium phosphate and/or amorphous calcium fluoride phosphate stabilised by phosphopeptides/phosphoproteins by addition of stannous ions. These complexes have anticariogenic properties useful to protect tooth structures as they remineralize (repair) early stages of dental caries and have other dental/medical applications (including anti-calculus, anti-erosion/corrosion and anti-dentinal hypersensitivity). Methods of making the complexes of the invention and of treatment or prevention of various dental conditions including dental caries, dental calculus, dental erosion/corrosion and dental hypersensitivity are also provided.

Abstract: A drug that contains chlorogenic acid is effective in treating chordoma. When administered to a patient in need thereof, chlorogenic acid can significantly inhibit the proliferation of chordoma cells, reduce the expression level of multi-drug resistance gene MDR1 of chordoma cells, reverse the multi-drug resistance of chordoma cells, and effectively treat chordoma disease.

Abstract: A stabilised hypochlorous solution is disclosed. The solution includes hypochlorous acid (HOCl), hypochlorite (ClO—), and chlorine (Cl—) that combine to provide a total chlorine concentration. The total chlorine concentration is at or below 300 ppm, the hypochlorous acid, measured by UV spectroscopy at 230 nm, is the predominant species, the hypochlorite, measured by UV spectroscopy at 290 nm, is present at significantly lower levels than that of the hypochlorous acid, such that a ratio of hypochlorous acid to hypochlorite is greater than 7.5:1. The solution has a pH of between about 7 and 4 and a shelf life of at least 12 months, at 22° C., such that the amount of hypochlorous present remains at above 80% of its starting concentration, and the pH remains above 4.

Abstract: This application provides, among other things, novel aqueous monophasic compositions useful for combining and delivering poorly compatible ingredients, for example to deliver effective levels of cationic antibacterial agents in combination with anionic polymers, e.g. that protect against erosion and staining, by addition of a stabilizing amount of a polyamine, e.g. lysine, and methods for making and using the same.

Abstract: The present invention concerns a method to prepare a filler with a hyaluronic acid, which has improved properties of chemical-physical stability over time and optimal viscosity for cutaneous injection. In particular the method comprises a first step in which the hyaluronic acid is crosslinked, and a subsequent step for the neutralization and hydration of the crosslinked hyaluronic acid.

Abstract: Dental compositions that comprise algae are disclosed. Methods of use of the dental compositions, including methods of reducing plaque on at least one tooth of an animal using the dental compositions, are also disclosed.

Abstract: Disclosed herein are aqueous compositions comprising fructose and methods of production thereof. A method for producing an aqueous composition comprising fructose can comprise, for example, conducting an enzymatic reaction by contacting water, sucrose, and a glucosyltransferase enzyme that synthesizes poly alpha-1,3-glucan having at least 30% alpha-1,3-linkages. A soluble fraction produced by such a reaction comprises at least about 55% fructose on a dry weight basis, and can be separated from insoluble poly alpha-1,3-glucan product(s), thereby providing an aqueous composition comprising fructose.

Abstract: Described herein are single-phase compositions and methods for its pharmaceutical and cosmetic use, comprising (i) a combination of N-acyl sarcosinate, (ii) an oxidative compound, and (iii) a buffering system in amounts and embodiments effective to protect the oxidative compounds from degradation prior to use and upon use and to enhance the efficacy of the composition in removing polymicrobial biofilms, reducing the re-growth of polymicrobial biofilms that leads to plaque formation, greater availability of chlorite ion for antimicrobial and cosmetic purposes, and effective oxidation of salivary biomolecules. When these single-phase compositions are comprised of a source of fluoride ion, they also achieve enhanced enamel fluoride uptake, higher enamel protection by enhanced remineralization and reduced demineralization of teeth when compared to US Pharmacopoeia Reference Dentifrice, prior known toothpastes comprising stabilized chlorine dioxide and comparable commercial dentifrices.

Abstract: The present invention is directed to a depot composition for sustained release delivery of buprenorphine with enhanced stability and bioavailability. The composition is an injectable, low viscosity liquid and can form a depot in situ capable of delivering therapeutic level of buprenorphine over a period of time from one week to 3 months.

Abstract: Oral care compositions comprising stannous ion source, neutral amino acid, and polyphosphate are provided for improved efficacy to help inhibit biofilm formation or help disrupt biofilm.

Abstract: The present invention relates to an oral plaque dispersion agent capable of effectively acting on dental plaque from the surface layer to the deep part thereof and exerting an excellent effect of dispersing the dental plaque. Specifically, the present invention relates to an oral plaque dispersion agent comprising (A) a water-soluble compound 3 or more of primary hydroxyl groups in the molecular structure and 100 or more and 200 or less of a chemical formula weight as an active component.

Abstract: Some embodiments described herein provide for a multi-component compositions and methods for its pharmaceutical and cosmetic use, comprising a combination of an aliphatic anionic compound, an oxidative compound, and a buffering system. Source of fluoride ion and other carriers are optional ingredients. The aliphatic anionic compound and the oxidative compound function together, in presence or absence of fluoride ion source, to protect the oxidative compounds from degradation prior to use and upon use, and to enhance the efficacy of the composition. In addition to achieving greater stability, combined effects of the aliphatic anionic compound, oxidative compound and source of fluoride ion achieve enhanced fluoride uptake, higher enamel protection by enhanced remineralization and reduced demineralization, increased plaque removal, reduced re-growth of plaque polymicrobial biofilm, greater amount of chlorite ion availability and effective oxidation of salivary biomolecules.

Abstract: A smokeless tobacco product or medicinal nicotine product includes nicotine and camphor dissolved in a non-flavored oily carrier. Preferably, the camphor is present in a concentration ranging from about 600 ppm to about 1300 ppm. Also disclosed are methods of making such products.

Abstract: A method of treating diseased tissue while healing the wound using a diode laser which generates a beam of light having a wavelength in the visible portion of the electromagnetic spectrum (400 nm-700 nm) at a laser power of 0.001 to 12 watts, used with intermittent stops to control tissue temperature and biostimulate epithelial regeneration when used with or without substrates. A method of treating diseased tissue using a laser light in the green wavelength range (520-570 nm) at a laser power of 0.001 W to 5 W. A method of treating diseased tissue using a laser light in the IR wavelength range (700-1400 nm) at a laser power of 0.001 W to 5 W.

Abstract: The invention provides compositions and methods for topically inhibiting, reducing or preventing growth or biofilm formation of caries-, gingivitis- and/or halitosis-causing bacteria. The composition includes at least about 0.005% (w/v) of tea polyphenols, a pH modulating agent for maintaining a pH of the composition above about 6.5, and at least about 1% (w/v) of a 3-carbon to a 24-carbon sugar alcohol. Also provided are food products or supplements incorporating such compositions.

Abstract: The disclosure describes compositions for dental varnishes, methods of making the compositions, and methods of using the compositions, such as in the treatment and prevention of hypersensitivity in teeth.

Abstract: Dentifrice containing silica particles having a d50 median particle size from 4 to 25 ?m, a BET surface area of less than 10 m2/g, and a total mercury intrusion pore volume from 0.2 to 1.5 cc/g, are disclosed.

Abstract: A preparation in the form of a powder containing: (a) at least one carotenoid, (b) at least one modified starch, and (c) sucrose; wherein the at least one carotenoid is present in the powder in an amount of 1 to 25% by weight, based on the weight of the powder; and wherein the at least one carotenoid and the sucrose are present in the powder in a ratio by weight of 1:2 to 1:80.

Abstract: Adhesive compositions exhibiting antimicrobial properties, good stability, long shelf lives and enhanced release of antimicrobial agents are described. In certain versions, the compositions also exhibit relatively high fluid handling capacities. The adhesive compositions inhibit microbial growth by more than 2 log after 24 hours contact and particularly more than 3.5 log after 6 hours contact. Also described are various medical articles using such adhesives and related methods.